The inaugural Advances in Onco-menopause International Conference, scheduled for October 30, 2026, will address treatment-induced menopause as an integral part of cancer survivorship care. According to Conference Chair Dr. Muna Al-Khaifi, managing these complex symptoms supports patients through treatment, promotes adherence, and contributes to better long-term outcomes.
Clinical Perspectives on Evidence-Based Menopause Care for Cancer Survivors
Cancer treatments frequently induce or accelerate menopause, impacting patients across multiple health domains. According to conference organizers, these effects extend to vasomotor symptoms, sexual and genitourinary health, cognition, sleep, bone and cardiometabolic health, fertility, body composition, and overall quality of life. The online event brings health care professionals together for a full day dedicated to examining current evidence and practical approaches.
Participants will explore vasomotor symptom management, exercise, nutrition, and metabolic health. As survivorship evolves, the meeting highlights the growing need to strengthen clinical knowledge and multi-disciplinary collaboration between oncology and menopause care specialists.
Did you know? Treatment-induced menopause can introduce unique clinical challenges, requiring specialized management strategies across primary care and oncology settings.
Multidisciplinary Approaches and Expert Collaboration
The program is designed to move beyond simply recognizing menopause-related concerns and focus on clinical action. According to session outlines, clinicians will examine the latest recommendations to navigate complex hormonal and non-hormonal treatment decisions.
Dr. Muna Al-Khaifi emphasizes that addressing these health shifts is vital for patient adherence during cancer treatment. The conference welcomes a broad spectrum of professionals, including primary care providers, medical, surgical and radiation oncologists, gynaecologists, internists, endocrinologists, nurses, nurse practitioners, pharmacists, psychologists, social workers, and allied health professionals.
Registration and Event Details
The Advances in Onco-menopause International Conference takes place entirely online on October 30, 2026. Clinicians and trainees interested in attending can access the full program through the official event website.
Early Bird registration closes on October 12, 2026. Attendees will gain practical strategies applicable across oncology, primary care, gynaecology, and survivorship settings to support long-term patient health.
Pro Tip for Clinicians
Review the comprehensive conference agenda early to identify cross-disciplinary sessions that bridge gaps between oncology protocols and primary menopause management.
Frequently Asked Questions
When is the Advances in Onco-menopause International Conference?
The conference takes place online on October 30, 2026, with Early Bird registration ending on October 12, 2026.
Who should attend the onco-menopause conference?
The event is tailored for primary care providers, oncologists, gynaecologists, endocrinologists, nurses, pharmacists, mental health professionals, allied health practitioners, and medical trainees.
Who is the Conference Chair?
The conference is chaired by Dr. Muna Al-Khaifi, MD, CCFP, MPH, who also serves as the Scientific Planning Lead.
What topics are covered in the conference program?
Sessions cover vasomotor symptom management, bone and cardiometabolic health, sexual health, genitourinary syndromes, cancer-related cognitive changes, menopausal hormone therapy, and exercise and nutrition.
Explore our latest coverage on survivorship care, and share your thoughts or questions in the comments below.
Related reading
- Social Media Driving Misuse of Alzheimer’s Blood Tests
- Dengue-Carrying Mosquitoes Expand Into Florida and New Territories
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)